Dana Investment Advisors Inc. Takes Position in LivaNova PLC $LIVN

Dana Investment Advisors Inc. acquired a new stake in LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 21,237 shares of the company’s stock, valued at approximately $1,112,000.

Several other large investors have also bought and sold shares of LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in LivaNova by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock worth $1,394,000 after acquiring an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of LivaNova by 4.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after purchasing an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after purchasing an additional 15,405 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after purchasing an additional 7,195 shares in the last quarter. Finally, Strs Ohio acquired a new stake in LivaNova during the first quarter valued at approximately $130,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several recent research reports. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Piper Sandler reissued an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research note on Thursday, February 19th. The Goldman Sachs Group restated a “neutral” rating and issued a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Barclays upped their target price on LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a report on Friday, January 9th. Finally, Stifel Nicolaus set a $80.00 price target on LivaNova in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $74.11.

LivaNova Stock Performance

Shares of LivaNova stock opened at $71.00 on Friday. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $71.92. The company has a quick ratio of 1.12, a current ratio of 1.36 and a debt-to-equity ratio of 0.29. The stock has a market cap of $3.88 billion, a PE ratio of -15.92 and a beta of 0.97. The business has a fifty day simple moving average of $64.59 and a 200-day simple moving average of $58.90.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm had revenue of $360.86 million during the quarter, compared to the consensus estimate of $354.31 million. During the same period in the prior year, the business earned $0.81 EPS. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, sell-side analysts anticipate that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 beat — LivaNova reported Q4 revenue of $360.9M (up ~12% YoY) and adjusted EPS of $0.86, topping consensus on both top and bottom lines; management highlighted organic growth across core businesses. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Raised FY2026 EPS guidance — management issued EPS guidance of $4.15–$4.25 versus consensus near $3.90, signaling stronger-than-expected margin and earnings leverage for the year. Revenue guidance was roughly in line with consensus (~$1.5B). LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Analyst upgrade/price-target lift — Needham raised its price target to $81 and kept a Buy rating, providing additional analyst support for the rally. Livanova (LIVN) PT Raised to $81 at Needham
• Positive Sentiment: Short interest fell materially in February (down ~16.6%), lowering potential short-squeeze risk and reducing bearish positioning. (Data released by exchanges; summary in earnings coverage.)
• Neutral Sentiment: New data partnership — LivaNova announced a data partnership with Orrum that could enhance its cardiac-care analytics and reimbursement narrative, but the commercial impact is still speculative. Could LivaNova’s (LIVN) Data Partnership With Orrum Quietly Reshape Its Cardiac Care Narrative?
• Neutral Sentiment: Earnings materials and call transcript released — slide deck and full call transcript are available for investors to review execution details and product cadence. LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Margin profile and GAAP metrics — despite adjusted EPS beats, LivaNova still shows pressure on GAAP margins (company-reported net margin metrics), which investors will watch as guidance is executed. LivaNova Q4 Earnings Snapshot

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.